1. Mesoporous silica nanoparticles/hydroxyapatite composite coated implants to locally inhibit osteoclastic activity.
- Author
-
Zhu M, Zhu Y, Ni B, Xie N, Lu X, Shi J, Zeng Y, and Guo X
- Subjects
- Animals, Bone Wires, Diphosphonates chemistry, Drug Carriers chemistry, Humans, Imidazoles chemistry, Osteoclasts drug effects, Porosity, Prostheses and Implants, Zoledronic Acid, Bone Resorption drug therapy, Coated Materials, Biocompatible chemistry, Diphosphonates pharmacology, Durapatite chemistry, Imidazoles pharmacology, Nanoparticles chemistry, Osteoclasts physiology, Silicon Dioxide chemistry
- Abstract
In an attempt to improve implant-bone integration and accelerate bone fracture healing from resisting osteoclastic resorption point of view, we have employed a novel procedure to develop a mesoporous silica nanoparticles/hydroxyapatite (MSNs/HA) composite coating onto stainless Kirschner wire substrate. Characterizations of the surface microstructures indicated enlarged specific surface area compared to HA-coated wires as control, thus the MSNs/HA composite coated implants are endowed with abilities to locally deliver biomedical substances and enhance fracture healing. Herein, zoledronic acid (ZOL) as a model drug, different doses of which were immobilized in the mesoporous coating toward decreasing osteoclastic resorption activity. The loading capacities of ZOL increased almost eight-folds to that of pure HA coating, and the introduction of MSNs obviously retarded ZOL release to achieve a more sustained release profile. After certain periods of osteoclast like cells co-culturing with ZOL contained wires, tartrat-resistant acid phosphatases (TRAP) staining of polynucleated cells and a pit formation assay were performed to investigate the ZOL dose-dependent anti-resorption activity. The promoted local effect on osteoclasts will be of clinical benefit to support implant integration and bone repair.
- Published
- 2014
- Full Text
- View/download PDF